TP53 and acute myeloid leukemia: For example, in their review of “personalized medicine for TP53 mutated MDS and acute myeloid leukemia,[35] the authors named the precision and targeted therapy for TP53 as “personalized.” Indeed, the quest for better suitability of therapy will lead to better disease targeting.